Zobrazeno 1 - 10
of 575
pro vyhledávání: '"Gerd R, Burmester"'
Autor:
Edward Keystone, Josef S Smolen, Gerd R Burmester, Slawomir Jeka, Pawel Hrycaj, Janusz Jaworski, Anna Dudek, Artur Racewicz, Agnieszka Zielinska, YunJu Bae, Rafal Wojciechowski, Marek Krogulec, Jakub Trefler, Katarzyna Kolossa, Magdalena Krajewska-Włodarczyk, Piotr Adrian Klimiuk, SungHyun Kim, GoEun Yang, YooBin Jung, JiWoo Hong
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Objectives To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA).Methods This double-blind, phase III study randomised (1:1) patients to receive CT-P47 or r-TCZ (8 mg/kg
Externí odkaz:
https://doaj.org/article/57062166f2dd4fe39a65b97114a32a54
Autor:
Jeffrey A. Sparks, Philippe Dieudé, Anna-Maria Hoffmann-Vold, Gerd R Burmester, Simon LF Walsh, Michael Kreuter, Christian Stock, Steven Sambevski, Margarida Alves, Paul Emery
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Background Patients with rheumatoid arthritis (RA) are at risk of developing interstitial lung disease (ILD), which is associated with high mortality. Screening tools based on risk factors are needed to decide which patients with RA should b
Externí odkaz:
https://doaj.org/article/7f168e26c2354e6d9a2a6c55793ae5b1
Autor:
Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S. Gensler
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 737-753 (2024)
Abstract Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondyl
Externí odkaz:
https://doaj.org/article/e351d86bf89749d7bfde8d923d44f476
Autor:
Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 157-175 (2024)
Abstract Introduction Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical tri
Externí odkaz:
https://doaj.org/article/7848bcb7d51248bd8d20a0519b6de718
Autor:
Rieke Alten, Gerd R. Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör, Khai Jing Ng, Jens Gerwien, Liliana Zaremba-Pechmann, Alan J. M. Brnabic, Bruno Fautrel
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1575-1595 (2023)
Abstract Introduction RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment along with patient baseline characteristics. Thi
Externí odkaz:
https://doaj.org/article/63d5ff311b2441d18921c0a0894d1ffb
Autor:
Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1255-1276 (2023)
Abstract Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spo
Externí odkaz:
https://doaj.org/article/34b105e8c7c24f45a0dae2316f33af1c
Autor:
Chiara Tani, Chiara Cardelli, Roberto Depascale, Anna Gamba, Luca Iaccarino, Andrea Doria, Matilde Bandeira, Sara Paiva Dinis, Vasco C. Romão, Emanuele Gotelli, Sabrina Paolino, Maurizio Cutolo, Niccolò Di Giosaffatte, Alessandro Ferraris, Paola Grammatico, Lorenzo Cavagna, Veronica Codullo, Carlomaurizio Montecucco, Valentina Longo, Lorenzo Beretta, Ilaria Cavazzana, Micaela Fredi, Silvia Peretti, Serena Guiducci, Marco Matucci-Cerinic, Stefano Bombardieri, Gerd R. Burmester, João E. Fonseca, Charissa Frank, Ilaria Galetti, Eric Hachulla, Ulf Müller-Ladner, Matthias Schneider, Vanessa Smith, Farah Tamirou, Jacob M. Van Laar, Ana Vieira, Rossella D'Urzo, Sara Cannizzo, Andrea Gaglioti, Diana Marinello, Rosaria Talarico, Marta Mosca
Publikováno v:
Journal of Translational Autoimmunity, Vol 7, Iss , Pp 100221- (2023)
Background: Vaccination is one of the most important measures to contain the COVID-19 pandemic, especially for frail patients. VACCINATE is a multicentre prospective observational study promoted by the European Reference Network on Rare and Complex C
Externí odkaz:
https://doaj.org/article/6535028b21df4f64b471e8d7b7b6052c
Autor:
Frank Behrens, Jürgen Rech, Jürgen Braun, Denis Poddubnyy, Gerd R Burmester, Uta Kiltz, Stephanie Finzel, Diamant Thaçi, Herbert Kellner, Karolina Benesova, Reinhard E Voll, Jan Brandt, Andrea Rubbert-Roth, David M Kofler, Klaus Krüger, Siegfried Wassenberg, Winfried Demary, Regina Max, Peter Kastner, Michaela Koehm, Ulrich von Hinüber, Raoul Bergner, Jan Brandt-Jürgens, Ann C Foldenauer, Tanja Rossmanith, Maren Sieburg, Rieke HE Alten, Arnd Kleye, David Kofler, Gabriele Lorenz, Holger Schwenke, Astrid Thiele, Jochen Walter
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Background The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored.Objective To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an
Externí odkaz:
https://doaj.org/article/b3acb669834f448d9e33b145ffe10884
Autor:
Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 53-70 (2022)
Abstract Introduction This exploratory analysis of FINCH 1 (NCT02889796) examined filgotinib (FIL) efficacy and safety in a subgroup of patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX; MTX-IR) who had four poor pr
Externí odkaz:
https://doaj.org/article/d5f278750ece4369b8287f893aae3cee
Autor:
Rieke Alten, Gerd R. Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Pedro Lopez-Romero, Walid Fakhouri, Inmaculada de la Torre, Liliana Zaremba-Pechmann, Thorsten Holzkämper, Bruno Fautrel
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 73-93 (2022)
Abstract Introduction RA-BE-REAL has the overall aim of defining a profile of patients with rheumatoid arthritis (RA) starting baricitinib or any other targeted synthetic (ts) or any biologic (b) disease-modifying antirheumatic drug (DMARD) for the f
Externí odkaz:
https://doaj.org/article/ab9bdc473f0647a5848b4e5f65379efc